ArticleFrontiers in public health2026
An explainable machine learning model for type B aortic dissection identification: development and internal evaluation.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Type B aortic dissection (TBAD) is a life-threatening cardiovascular emergency that requires timely recognition. This study aimed to develop and internally evaluate an explainable machine learning model for identifying existing TBAD using routinely available clinical history and admission laboratory data. Methods: This single-center retrospective case-control study included 1,640 participants, comprising 854 patients with CTA-confirmed TBAD and 786 hospitalized controls who underwent whole-aorta CTA and were confirmed not to have aortic dissection. Demographic characteristics, medical history, and admission laboratory test results were collected as 38 initial candidate features. Least absolute shrinkage and selection operator (LASSO) regression was applied to identify key discriminative variables. Machine-learning models based on eight algorithms were then developed and compared: support vector machine (SVM), gradient boosting machine (GBM), neural network, extreme gradient boosting (XGBoost), k-nearest neighbors (KNN), adaptive boosting (AdaBoost), light gradient boosting machine (LightGBM), and categorical boosting (CatBoost). Hyperparameters were tuned in the training set using grid search and repeated 10-fold cross-validation with five repeats. Model discrimination was evaluated in the held-out internal test set using the area under the receiver operating characteristic curve (AUC). The final representative model was selected for exploratory interpretation using SHapley Additive exPlanations (SHAP). Results: LASSO regression identified five predictors: hypertension, white blood cell count, lymphocyte percentage, basophil percentage, and monocyte count. Several models showed comparable discrimination in the held-out internal test set. The neural network model achieved an AUC of 0.883 in the training set and 0.852 in the held-out internal test set, with 95% confidence intervals of 0.864-0.902 and 0.819-0.885, respectively. Based on the ROC curve analysis, the neural network model showed relatively favorable discrimination and was therefore selected as the final representative model for exploratory SHAP-based interpretation. SHAP analysis indicated that lymphocyte percentage, hypertension, monocyte count, white blood cell count, and basophil percentage were the major contributors to the predictions of the final model, with lymphocyte percentage showing the highest mean absolute SHAP value. Conclusion: This study developed and internally evaluated an explainable machine-learning model for identifying existing TBAD in a single-center CTA-confirmed retrospective case-control cohort. Given the lack of external validation, this study should be regarded as exploratory. External validation in clinically relevant acute symptomatic populations is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.